Core Insights - Astrazeneca reported $13.59 billion in revenue for Q1 2025, a year-over-year increase of 7.2% [1] - The EPS for the same period was $1.24, compared to $1.03 a year ago, representing a surprise of +12.73% over the consensus estimate [1][3] - The revenue fell short of the Zacks Consensus Estimate by -0.66% [1] Financial Performance - Astrazeneca's stock has returned -4.9% over the past month, underperforming the Zacks S&P 500 composite's -0.8% change [3] - The company currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3] Key Product Metrics - Oncology product Tagrisso generated $678 million in the U.S., slightly below the average estimate of $684.78 million [4] - BioPharmaceuticals product Farxiga in Established RoW reported $120 million, exceeding the estimate of $101.67 million, with a year-over-year change of +11.1% [4] - Oncology product Enhertu in Established RoW achieved $19 million, compared to the estimate of $21.59 million, reflecting a year-over-year increase of +46.2% [4] - Enhertu in Europe reported $43 million, surpassing the estimate of $36.98 million, with a year-over-year change of +65.4% [4] - BioPharmaceuticals product Symbicort generated $723 million, below the estimate of $772.02 million [4] - Pulmicort reported $158 million, compared to the estimate of $197.96 million [4] - Crestor achieved $316 million, exceeding the estimate of $294.03 million, with a year-over-year change of +6.4% [4] - Seloken/Toprol-XL reported $161 million, slightly above the estimate of $154.45 million, with a year-over-year change of -2.4% [4] - Tagrisso worldwide generated $1.68 billion, slightly above the estimate of $1.67 billion, reflecting a year-over-year change of +5.3% [4] - Synagis reported $112 million, below the estimate of $132.88 million, with a year-over-year change of -34.5% [4] - Fasenra achieved $418 million, exceeding the estimate of $379.51 million [4] - Brilinta reported $305 million, above the estimate of $263.03 million, with a year-over-year change of -5.6% [4]

Core Insights - Corning reported revenue of $3.68 billion for the quarter ended March 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate by 3.87% [1] - The company's EPS for the quarter was $0.54, an increase from $0.38 in the same quarter last year, exceeding the consensus estimate of $0.50 by 8.00% [1] Financial Performance - Net Sales in Display Technologies reached $905 million, slightly below the average estimate of $912.96 million, with a year-over-year change of +3.8% [4] - Net Sales in Optical Communications were $1.36 billion, exceeding the estimated $1.27 billion, marking a significant year-over-year increase of +45.7% [4] - Net Sales in Hemlock and Emerging Growth Businesses totaled $244 million, falling short of the average estimate of $321.84 million, representing a year-over-year decline of -21.5% [4] - Net Sales in Life Sciences were $234 million, below the average estimate of $249.16 million, with a slight year-over-year decrease of -0.9% [4] - Net Sales in Specialty Materials reached $501 million, surpassing the average estimate of $468.60 million, reflecting a year-over-year increase of +10.4% [4] Segment Performance - Segment Net Income for Optical Communications was $201 million, exceeding the average estimate of $169.93 million [4] - Segment Net Income for Display Technologies was $243 million, above the average estimate of $221.66 million [4] - Segment Net Income for Life Sciences was $13 million, below the average estimate of $19.50 million [4] - Segment Net Income for Specialty Materials was $74 million, slightly above the average estimate of $72.16 million [4] - Segment Net Income for Hemlock and Emerging Growth Businesses reported a loss of -$16 million, worse than the average estimate of -$7.78 million [4] Stock Performance - Corning's shares have returned -3.7% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

三、分红送配方案情况 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 9946.21万股，累计占流通股比： 52.67%，较上期变化： 162.17万股。 | 名称 | 持有数量(万股) | 占总股本比例 (%) | 增减情况(万 股) | | --- | --- | --- | --- | | 陈洪民 | 3893.70 | 20.62 | 不变 | | 上海晶优新能源有限公司 | 2169.14 | 11.49 | 不变 | | 张宇 | 1600.80 | 8.48 | 不变 | | 陈伟 | 672.34 | 3.56 | 不变 | | 陈小科 | 560.12 | 2.97 | 不变 | | 江苏科华投资管理有限公司 | 388.92 | 2.06 | 不变 | | 郑文涌 | 210.11 | 1.11 | 新进 | | 薛勇 | 189.43 | 1.00 | 不变 | | 科华控股（603161）股份有限公司回购专用证券账 | | | | | 户 | 134.62 | 0.71 | 不变 | | 高盛公司有限责任公司 | 127.03 | 0.67 | 新 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 李刚 | 1074.50 | 19.19 | 不变 | | 中新苏州工业园区创业投资有限公司 | 249.93 | 4.46 | -30.00 | | 上海华芯创业投资企业 | 216.49 | 3.87 | -47.71 | | 苏州昶众企业管理咨询中心(有限合伙) | 185.00 | 3.30 | 不变 | | 梅嘉欣 | 167.04 | 2.98 | 不变 | | 胡维 | 158.50 | 2.83 | 不变 | | 信澳先进智造股票型 | 144.85 | 2.59 | 3.30 | | 苏州工业园区创业投资引导基金管理中心 | 124.23 | 2.22 | 不变 | | 信澳领先增长混合A | 116.03 | 2.07 | 12.10 | | 苏州昶恒企业管理咨询企业(有限合伙) | 93.86 | 1.68 | 不变 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 | 报告期指标 | 2025年一 ...

Financial Performance - The company reported a basic earnings per share (EPS) of 0.0170 yuan for Q1 2025, representing a 13.33% increase compared to 0.0150 yuan in Q1 2024, but a decrease from 0.0280 yuan in Q1 2023 [1] - The total revenue for Q1 2025 was 120.49 billion yuan, showing a 19.97% increase from 100.43 billion yuan in Q1 2024 and an increase from 104 billion yuan in Q1 2023 [1] - The net profit for Q1 2025 was 0.23 billion yuan, a 9.52% increase from 0.21 billion yuan in Q1 2024, but a decrease from 0.39 billion yuan in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 0.66%, up 22.22% from 0.54% in Q1 2024, but down from 1.04% in Q1 2023 [1] - The net asset per share decreased by 8.63% to 2.54 yuan in Q1 2025 from 2.78 yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 66,655.07 million shares, accounting for 48.62% of the circulating shares, with a decrease of 500.35 million shares compared to the previous period [1] - The largest shareholder, Baosheng Group Co., Ltd., holds 43,740.64 million shares, representing 31.90% of the total share capital, with no change [2] - The second-largest shareholder, Anyi Junjing Shengda Equity Investment Partnership (Limited Partnership), holds 6,857.68 million shares, a decrease of 649.00 million shares [2] - New entrants among the top shareholders include Bi Sheng, Hong Xiaoping, and Lan Yun, each holding 339.02 million, 315.00 million, and 289.97 million shares respectively [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [2]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0040 | 0.0050 | -20 | 0.0050 | | 每股净资产（元） | 2.34 | 2.31 | 1.3 | 2.3 | | 每股公积金(元) | 0.27 | 0.27 | 0 | 0.27 | | 每股未分配利润(元) | 0.82 | 0.80 | 2.5 | 0.79 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.07 | 2.25 | -8 | 2.43 | | 净利润(亿元) | 0.07 | 0.07 | 0 | 0.08 | | 净资产收益率(%) | 0.19 | 0.22 | -13.64 | 0.22 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 61020.99万股，累计占流通股比： 41.77%，较上期变化： -897.51万股。 ...

| 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 国投种业科技有限公司 | 12280.30 | 20.00 | 不变 | | 合肥市建设投资控股(集团)有限公司 | 5673.99 | 9.24 | 不变 | | 嘉实农业产业股票A | 1220.57 | 1.99 | -85.53 | | 宋钢 | 444.25 | 0.72 | 53.16 | | 朱黎辉 | 410.02 | 0.67 | -2.00 | | 海南波莲科技有限公司 | 405.00 | 0.66 | 2.00 | | 基本养老保险基金九零三组合 | 358.16 | 0.58 | 新进 | | 戴飞 | 321.78 | 0.52 | 10.00 | | 丁建军 | 318.94 | 0.52 | 45.83 | | 王淑芬 | 294.45 | 0.48 | 13.85 | | 较上个报告期退出前十大股东有 | | | | | 万家内需增长一年持有期混合 | 373.40 | 0.61 | 退出 | 一、主要会计数据和财务指标 三、分红送配方案情 ...

一、主要会计数据和财务指标 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 北京顺义大龙城乡建设开发有限公司 | 39591.66 | 47.70 | 不变 | | 王德富 | 693.11 | 0.84 | 305.00 | | 王莹 | 536.32 | 0.65 | 160.00 | | 王淑霞 | 528.56 | 0.64 | 145.58 | | 金元顺安元启灵活配置混合 | 413.14 | 0.50 | 新进 | | 许冬娥 | 368.78 | 0.44 | 不变 | | 牛世宗 | 291.99 | 0.35 | 60.00 | | 秦立彬 | 290.00 | 0.35 | 新进 | | 谷锡钦 | 250.06 | 0.30 | 新进 | | 李炜林 | 246.00 | 0.30 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 张秀 | 335.06 | 0.40 | 退出 | | 胡声健 | 278.00 | 0.33 | 退出 | | 高盛公司有限责任公司 | 240.3 ...

一、主要会计数据和财务指标 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 26785.93万股，累计占流通股比： 44.44%，较上期变化： -54.42万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 香港南海洋行(国际)有限公司 | 9212.32 | 15.28 | 不变 | | 深圳广聚实业有限公司 | 7366.68 | 12.22 | 不变 | | 深圳市能源集团有限公司 | 6510.61 | 10.80 | 不变 | | 曾颖 | 715.96 | 1.19 | 不变 | | GUOTAI JUNAN SECURITIES (HONG KONG) LIMITED | 632.68 | 1.05 | -26.61 | | 李宝琴 | 567.02 | 0.94 | -16.56 | | 招商证券(香港)有限公司 | 543.82 | 0.90 | 不变 | | BOCI SECURITIES LIMITED | 431.06 ...

Financial Performance - The company reported a basic earnings per share of -0.0700 yuan for Q1 2025, a decrease of 250% compared to -0.0200 yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.18 billion yuan, reflecting a 350% decline from -0.04 billion yuan in Q1 2024 [1] - Operating revenue decreased by 26.54% to 3.1 billion yuan in Q1 2025, down from 4.22 billion yuan in Q1 2024 [1] - The return on equity was -4.09% in Q1 2025, a significant drop from -0.81% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 14,401.24 million shares, accounting for 59.88% of the circulating shares, which is a decrease of 948.87 million shares from the previous period [2] - Major shareholders include Shandong Huifa Investment Co., Ltd. with 6,950.76 million shares (28.90%), and Hui Zengyu with 5,088.50 million shares (21.16%), both remaining unchanged [3] - New entrants among the top shareholders include UBS AG, Morgan Stanley & Co. International PLC, and several others, while previous shareholders such as Yang Hong and Zhang Yuan have exited [3] Dividend Policy - The company has announced that it will not distribute dividends or bonus shares this period [4]